CNTB: Rademikibart reduced treatment failure by 66% and improved FEV₁ rapidly in acute asthma
A Phase 2 trial of rademikibart in acute asthma exacerbations showed a 66% reduction in treatment failure versus placebo and rapid, significant FEV₁ improvement, with a favorable safety profile. These results support further development and suggest substantial clinical and economic impact.Original…